BriaCell Partners with Memorial Sloan Kettering to Accelerate Development of Next-Generation Personalized Immunotherapy

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ pl...

October 22, 2025 | Wednesday | News
Adcytherix Raises €105 Million Series A to Advance Next-Generation Antibody–Drug Conjugates with Novel Payloads

Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...

October 20, 2025 | Monday | News
Azurity Pharmaceuticals Receives FDA Approval for Ferabright™, the First Iron-Based MRI Contrast Agent for Brain Tumour Imaging

Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...

October 20, 2025 | Monday | News
NuCana’s NUC-3373 Plus Pembrolizumab Shows Durable Responses in Heavily Pre-Treated Cancer Patients

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient wi...

October 16, 2025 | Thursday | News
Corventum Secures FDA Clearance for IND of CVT-130 to Prevent Chemotherapy-Induced Cardiotoxicity

-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective,  announced the clea...

October 15, 2025 | Wednesday | News
AstraZeneca at ESMO 2025: Advancing Oncology Across Breast, Bladder, Gastric, Lung, and Prostate Cancers

Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in ...

October 14, 2025 | Tuesday | News
Bicara Therapeutics’ Ficerafusp Alfa Receives FDA Breakthrough Therapy Designation for HPV-Negative Head and Neck Cancer

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patien...

October 14, 2025 | Tuesday | News
Immutep’s Phase III TACTI-004 Trial Surpasses 170 Patients Enrolled, On Track for Futility Analysis in Early 2026

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the...

October 13, 2025 | Monday | News
Greenwich LifeSciences Expands Phase III FLAMINGO-01 Breast Cancer Trial to Austria

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...

October 10, 2025 | Friday | News
Greenwich LifeSciences Expands FLAMINGO-01 Phase III Breast Cancer Trial to Belgium

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...

October 03, 2025 | Friday | News
Concept Life Sciences Expands Integrated Drug Discovery Facilities in High Peak

Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, announces the official openin...

September 30, 2025 | Tuesday | News
Philips Unveils Next-Generation CT and Helium-Free MR Systems to Transform Precision and Sustainability in Radiation Therapy

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...

September 29, 2025 | Monday | News
ME Therapeutics Secures U.S. Patent for Lead G-CSF Antibody Candidate to Advance Cancer Immunotherapies

ME Therapeutics Holdings Inc. a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased ...

September 29, 2025 | Monday | News
Zimmer Biomet Secures Japan PMDA Approval for World’s First Orthopedic Implants with Iodine Technology

  Zimmer Biomet Holdings, Inc., a global leader in medical technology, announced that Japan’s Pharmaceutical and Medical Devices Agency (PMDA) ...

September 26, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close